针对 COVID-19 的潜在治疗药物：目前我们所了解的情况。
Potential therapeutic agents against COVID-19: What we know so far.
机构信息
Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Faculty of Pharmacy, National Yang-Ming University, Taipei, Taiwan, ROC.
出版信息
J Chin Med Assoc. 2020 Jun;83(6):534-536. doi: 10.1097/JCMA.0000000000000318.
Abstract
The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.
摘要
新型冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒 2 引起的新发传染病，目前仍在全球范围内持续蔓延。具有明确疗效的治疗或预防人类冠状病毒感染的药物或疫苗亟待开发，目前正在全球范围内大力研究。本综述总结了目前在研的有治疗潜力的药物，如洛匹那韦/利托那韦、瑞德西韦、法匹拉韦、氯喹、羟氯喹、干扰素、利巴韦林、托珠单抗、沙利鲁单抗等。目前正在开展更多的临床试验，以进一步确认这些药物治疗 COVID-19 的疗效和安全性。
相似文献
1
Potential therapeutic agents against COVID-19: What we know so far.针对 COVID-19 的潜在治疗药物：目前我们所了解的情况。
J Chin Med Assoc. 2020 Jun;83(6):534-536. doi: 10.1097/JCMA.0000000000000318.
2
Some drugs for COVID-19.一些用于治疗新冠肺炎的药物。
Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50.
3
Race to find COVID-19 treatments accelerates.寻找新冠病毒治疗方法的竞赛加速。
Science. 2020 Mar 27;367(6485):1412-1413. doi: 10.1126/science.367.6485.1412.
4
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.具有治疗新型呼吸道 2019 冠状病毒潜力的化合物。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.00399-20.
5
Clinical Trials of Repurposed Antivirals for SARS-CoV-2.抗 SARS-CoV-2 再利用抗病毒药物的临床试验。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01101-20.
6
Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.瑞德西韦、洛匹那韦/利托那韦和氯喹/羟氯喹影响新型 SARS-CoV-2 的抗病毒机制研究进展。
Biomed Pharmacother. 2020 Nov;131:110668. doi: 10.1016/j.biopha.2020.110668. Epub 2020 Aug 24.
7
[From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic].[疫情期间冠状病毒感染重症病例抗病毒治疗从经验医学到科学证据]
Med Intensiva (Engl Ed). 2020 Nov;44(8):509-512. doi: 10.1016/j.medin.2020.04.009. Epub 2020 Apr 22.
8
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.新型冠状病毒治疗药物的安全性、临床应用和抗病毒研究概述。
J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13.
9
Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.用于 SARS-CoV-2 治疗的潜在抗病毒药物：临床前发现和正在进行的临床研究。
In Vivo. 2020 Jun;34(3 Suppl):1597-1602. doi: 10.21873/invivo.11949.
10
Treatment of SARS-CoV-2: How far have we reached?新型冠状病毒肺炎的治疗：我们已经取得了多大进展？
Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25.
引用本文的文献
1
Global Perspective on COVID-19 Therapies, Cardiovascular Outcomes, and Implications for Long COVID: A State-of-the-Art Review.关于新冠病毒治疗、心血管结局及对新冠长期症状影响的全球视角：最新综述
J Community Hosp Intern Med Perspect. 2024 Mar 4;14(2):58-66. doi: 10.55729/2000-9666.1308. eCollection 2024.
2
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.冠状病毒感染的叙述性概述：临床体征和症状、病毒进入和复制、治疗方式和管理。
Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058.
3
[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)].[新型冠状病毒肺炎的药物治疗：传染病与脓毒症工作组（GTEIS）及输血与血液制品工作组（GTTH）的叙述性综述]
Med Intensiva. 2021 Mar;45(2):104-121. doi: 10.1016/j.medin.2020.06.017. Epub 2020 Jul 11.
4
A Mini-Review on the Common Antiviral Drug Targets of Coronavirus.冠状病毒常见抗病毒药物靶点的小型综述
Microorganisms. 2024 Mar 17;12(3):600. doi: 10.3390/microorganisms12030600.
5
FACTORS AFFECTING PROGNOSIS AND MORTALITY IN SEVERE COVID-19 PNEUMONIA PATIENTS.影响重症 COVID-19 肺炎患者预后和死亡率的因素。
Acta Clin Croat. 2023 Apr;62(1):106-114. doi: 10.20471/acc.2023.62.01.13.
6
Prolonged Exposure to Remdesivir Inhibits the Human Ether-A-Go-Go-Related Gene Potassium Current.雷米地韦持续暴露抑制人醚-α--go-go 相关基因钾电流。
J Cardiovasc Pharmacol. 2023 Sep 1;82(3):212-220. doi: 10.1097/FJC.0000000000001449.
7
The association between dietary intakes of zinc, vitamin C and COVID-19 severity and related symptoms: A cross-sectional study.膳食锌、维生素 C 摄入与 COVID-19 严重程度及相关症状的关联：一项横断面研究。
Clin Nutr ESPEN. 2023 Jun;55:244-250. doi: 10.1016/j.clnesp.2023.03.013. Epub 2023 Mar 21.
8
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.抗靶标，抗 SARS-CoV-2 先导物，药物，以及药物发现遗传学联盟的视角。
J Med Chem. 2023 Mar 23;66(6):3664-3702. doi: 10.1021/acs.jmedchem.2c01229. Epub 2023 Mar 1.
9
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody.通过抗白细胞介素-6 受体抗体克服癌症相关成纤维细胞诱导的免疫抑制。
Cancer Immunol Immunother. 2023 Jul;72(7):2029-2044. doi: 10.1007/s00262-023-03378-7. Epub 2023 Feb 10.
10
Evaluation of Retinal Microvascular Impairment after COVID-19 and its Clinical Correlates Using Optical Coherence Tomography Angiography.评估 COVID-19 后视网膜微血管损伤及其与临床相关因素的关系：应用光学相干断层血管造影术。
Turk J Ophthalmol. 2022 Oct 28;52(5):324-330. doi: 10.4274/tjo.galenos.2022.87036.
本文引用的文献
1
Effective treatment of severe COVID-19 patients with tocilizumab.托珠单抗治疗重症 COVID-19 患者有效。
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975. doi: 10.1073/pnas.2005615117. Epub 2020 Apr 29.
2
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study.法匹拉韦治疗新型冠状病毒肺炎的实验性治疗：一项开放标签对照研究。
Engineering (Beijing). 2020 Oct;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007. Epub 2020 Mar 18.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
5
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
6
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学：对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.
9
First Case of 2019 Novel Coronavirus in the United States.美国首例 2019 新型冠状病毒病例。
N Engl J Med. 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191. Epub 2020 Jan 31.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
Zotero 插件